{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T10:36:06Z","timestamp":1781519766225,"version":"3.54.1"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.phrs.2014.05.001","type":"journal-article","created":{"date-parts":[[2014,5,14]],"date-time":"2014-05-14T16:31:58Z","timestamp":1400085118000},"page":"39-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Is generic rifaximin still a poorly absorbed antibiotic? A comparison of branded and generic formulations in healthy volunteers"],"prefix":"10.1016","volume":"85","author":[{"given":"Corrado","family":"Blandizzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Claudio","family":"Viscomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Marzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Scarpignato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2014.05.001_bib0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1006\/phrs.1996.0055","article-title":"Regulatory status of medicinal products for human beings in the European Union. The role of generic products","volume":"34","author":"Slavik","year":"1996","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.phrs.2014.05.001_bib0010","series-title":"Guideline on the investigation of bioequivalence. CPMP\/EWP\/QWP\/1401\/98 Rev. 1","author":"EMA The European Agency for the Evaluation of Medicinal Products","year":"2010"},{"key":"10.1016\/j.phrs.2014.05.001_bib0015","series-title":"HHS\/FDA Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products \u2013 General considerations","year":"2003"},{"key":"10.1016\/j.phrs.2014.05.001_bib0020","series-title":"Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability. Annex 7. WHO Technical Report Series, No. 937","author":"World Health Organization","year":"2006"},{"key":"10.1016\/j.phrs.2014.05.001_bib0025","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2165\/00003088-200342090-00002","article-title":"Selecting antibacterials for outpatient parenteral antimicrobial therapy: pharmacokinetic\u2013pharmacodynamic considerations","volume":"42","author":"Slavik","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.phrs.2014.05.001_bib0030","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1586\/14787210.4.3.479","article-title":"Influence of pharmacokinetics\/pharmacodynamics of antibacterials in their dosing regimen selection","volume":"4","author":"Scaglione","year":"2006","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.phrs.2014.05.001_bib0035","series-title":"Note for guidance on the clinical requirements for locally applied, locally acting products containing known constituents. CPMP\/EWP\/239\/95","author":"EMA The European Agency for the Evaluation of Medicinal Products","year":"1995"},{"key":"10.1016\/j.phrs.2014.05.001_bib0040","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1517\/17425255.2.4.591","article-title":"The road map to oral bioavailability: an industrial perspective","volume":"2","author":"Thomas","year":"2006","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.phrs.2014.05.001_bib0045","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1517\/17425255.3.4.469","article-title":"Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans","volume":"3","author":"Hurst","year":"2007","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.phrs.2014.05.001_bib0050","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.addr.2003.10.008","article-title":"Drug polymorphism and dosage form design: a practical perspective","volume":"56","author":"Singhal","year":"2004","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.phrs.2014.05.001_bib0055","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.addr.2003.10.007","article-title":"Impact of solid state properties on developability assessment of drug candidates","volume":"56","author":"Huang","year":"2004","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.phrs.2014.05.001_bib0060","first-page":"317","article-title":"Expanding the scope of crystal form evaluation in pharmaceutical science","volume":"9","author":"Peterson","year":"2006","journal-title":"J Pharm Pharm Sci"},{"key":"10.1016\/j.phrs.2014.05.001_bib0065","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev-chembioeng-061010-114224","article-title":"Crystal polymorphism in chemical process development","volume":"2","author":"Lee","year":"2011","journal-title":"Annu Rev Chem Biomol Eng"},{"key":"10.1016\/j.phrs.2014.05.001_bib0070","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/jps.2600560712","article-title":"Effect of polymorphism on the absorption of chloramphenicol from chloramphenicol palmitate","volume":"56","author":"Aguiar","year":"1967","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.phrs.2014.05.001_bib0075","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0378-5173(84)90210-2","article-title":"Effect of crystal form on the oral absorption of phenylbutazone","volume":"21","author":"Pandit","year":"1984","journal-title":"Int J Pharm"},{"key":"10.1016\/j.phrs.2014.05.001_bib0080","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1248\/cpb.29.268","article-title":"Relationship between polymorphism and bioavailability of amobarbital in the rabbit","volume":"29","author":"Kato","year":"1981","journal-title":"Chem Pharm Bull"},{"key":"10.1016\/j.phrs.2014.05.001_bib0085","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1248\/cpb.49.1321","article-title":"Characterisation of polymorphs of a novel quinolinone derivative TA-270 (4-hydroxy-1-methyl-3-octyloxy-sinapinoylamino-2(1H)-quinolinone)","volume":"49","author":"Kimura","year":"2001","journal-title":"Chem Pharm Bull"},{"key":"10.1016\/j.phrs.2014.05.001_bib0090","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1023\/A:1011052932607","article-title":"Ritonavir: an extraordinary example of conformational polymorphism","volume":"18","author":"Bauer","year":"2001","journal-title":"Pharm Res"},{"key":"10.1016\/j.phrs.2014.05.001_bib0095","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1021\/jm00145a020","article-title":"4-Deoxypyrido [1\u2032,2\u2032:1,2]imidazo[5,4-c]rifamycin SV derivatives. A new series of semisynthetic rifamycins with high antibacterial activity and low gastroenteric absorption","volume":"28","author":"Marchi","year":"1985","journal-title":"J Med Chem"},{"issue":"Suppl. 1","key":"10.1016\/j.phrs.2014.05.001_bib0100","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000081990","article-title":"Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential","volume":"51","author":"Scarpignato","year":"2005","journal-title":"Chemotherapy"},{"issue":"Suppl. 1","key":"10.1016\/j.phrs.2014.05.001_bib0105","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000089776","article-title":"Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic","volume":"73","author":"Scarpignato","year":"2006","journal-title":"Digestion"},{"key":"10.1016\/j.phrs.2014.05.001_bib0110","unstructured":"European Pharmacopoeia. Rifaximin (Revised Monograph) Suppl. 2011;7.1:2362."},{"key":"10.1016\/j.phrs.2014.05.001_bib0115","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1039\/b717887e","article-title":"Crystal forms of rifaximin and their effect on pharmaceutical properties","volume":"10","author":"Viscomi","year":"2008","journal-title":"CrystEngComm"},{"key":"10.1016\/j.phrs.2014.05.001_bib0120","series-title":"Polymorphism in pharmaceutical solids","first-page":"1","article-title":"Theory and origin of polymorphism","author":"Grant","year":"1999"},{"key":"10.1016\/j.phrs.2014.05.001_bib0125","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.addr.2003.10.005","article-title":"General principles of pharmaceutical solid polymorphism: a supramolecular perspective","volume":"56","author":"Rodriguez-Spong","year":"2004","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.phrs.2014.05.001_bib0130","first-page":"70","article-title":"Rifaximin powder, process for preparing the same and controlled release compositions containing said rifaximin useful for obtaining long-lasting effect","volume":"1079","author":"Viscomi","year":"2011","journal-title":"WHO"},{"issue":"Suppl. 2","key":"10.1016\/j.phrs.2014.05.001_bib0135","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1590-8658(10)60368-4","article-title":"A randomised, crossover study to evaluate the safety and the pharmacokinetic profiles of a single oral dose (400mg) of amorphous rifaximin in comparison with a single oral dose (400mg) of Normix\u00ae (rifaximin polymorph \u03b1) in healthy volunteers","volume":"42","author":"Marzo","year":"2010","journal-title":"Dig Liv Dis"},{"key":"10.1016\/j.phrs.2014.05.001_bib0140","unstructured":"Normix\u00ae Summary of Product Characteristics (Revision September 1, 2007), Section 5.1."},{"key":"10.1016\/j.phrs.2014.05.001_bib0145","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2125.2009.03399.x","article-title":"Lack of pharmacokinetic bioequivalence between generic and branded amoxicillin formulations. A post-marketing clinical study on healthy volunteers","volume":"68","author":"Del Tacca","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.phrs.2014.05.001_bib0150","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S1043-6618(05)80028-3","article-title":"Open questions in bioequivalence","volume":"32","author":"Marzo","year":"1995","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.phrs.2014.05.001_bib0155","volume":"vol. 263 (Suppl. 247)","author":"Italian Medicines Agency (AIFA)","year":"2010"},{"key":"10.1016\/j.phrs.2014.05.001_bib0160","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1006\/phrs.1997.0254","article-title":"Clinical pharmacokinetic registration file for NDA and ANDA procedures","volume":"36","author":"Marzo","year":"1997","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.phrs.2014.05.001_bib0165","series-title":"Guidance for industry. ANDAs: pharmaceutical solid polymorphism. Chemistry, manufacturing and controls information","author":"Food and Drug Administration (FDA)","year":"2007"},{"key":"10.1016\/j.phrs.2014.05.001_bib0170","doi-asserted-by":"crossref","first-page":"6404","DOI":"10.1039\/c2ce25920f","article-title":"The structure\u2013property relationship of four crystal forms of rifaximin","volume":"14","author":"Braga","year":"2012","journal-title":"CrystEngComm"},{"key":"10.1016\/j.phrs.2014.05.001_bib0175","first-page":"54","article-title":"Avoiding adverse reactions. Effective lower-dose drug therapies for older patients","volume":"55","author":"Cohen","year":"2000","journal-title":"Geriatrics"},{"key":"10.1016\/j.phrs.2014.05.001_bib0180","first-page":"49","article-title":"Tools to define the relevance of PK\/PD parameters to the efficacy, toxicity and emergence of resistance of antimicrobials","volume":"10","author":"Hickey","year":"2007","journal-title":"Curr Opin Drug Discov Dev"},{"key":"10.1016\/j.phrs.2014.05.001_bib0185","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2165\/00002018-200629030-00004","article-title":"Safety and tolerability of the antibacterial rifaximin in the treatment of travellers\u2019 diarrhoea","volume":"29","author":"Ericsson","year":"2006","journal-title":"Drug Saf"},{"key":"10.1016\/j.phrs.2014.05.001_bib0190","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","article-title":"Rifaximin treatment in hepatic encephalopathy","volume":"362","author":"Bass","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2014.05.001_bib0195","series-title":"Salix Pharmaceuticals Inc Xifaxan\u2122 550 Prescribing Information","year":"2014"},{"key":"10.1016\/j.phrs.2014.05.001_bib0200","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/apt.12531","article-title":"Commentary: towards an effective and safe treatment of small intestine bacterial overgrowth","volume":"38","author":"Scarpignato","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.phrs.2014.05.001_bib0205","series-title":"Rifaximin, a poorly absorbed antibiotic. Pharmacology and clinical use","first-page":"1","year":"2005"},{"key":"10.1016\/j.phrs.2014.05.001_bib0210","series-title":"Bacterial flora in digestive disease. Focus on rifaximin","first-page":"1","year":"2006"},{"key":"10.1016\/j.phrs.2014.05.001_bib0215","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/00003088-200140050-00002","article-title":"Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibiotics","volume":"40","author":"Burman","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.phrs.2014.05.001_bib0220","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(03)14333-4","article-title":"Tuberculosis","volume":"362","author":"Frieden","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2014.05.001_bib0225","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/00006454-199809000-00013","article-title":"Azithromycin compared with rifampin for eradication of nasopharyngeal colonization by Neisseria meningitidis","volume":"17","author":"Girgis","year":"1998","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.phrs.2014.05.001_bib0230","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/infdis\/171.3.728","article-title":"Eradication of nasopharyngeal carriage of Neisseria meningitidis in children and adults in rural Africa: a comparison of ciprofloxacin and rifampicin","volume":"171","author":"Cuevas","year":"1995","journal-title":"J Infect Dis"},{"key":"10.1016\/j.phrs.2014.05.001_bib0235","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S0140-6736(88)92069-7","article-title":"Comparative efficacy of ceftriaxone and rifampicin in eradicating pharyngeal carriage of group A Neisseria meningitidis","volume":"1","author":"Schwartz","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2014.05.001_bib0240","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1179\/joc.2002.14.1.33","article-title":"A 10-year survey of Mycobacterium tuberculosis isolates in Pavia and their drug resistance: a comparison with other Italian reports","volume":"14","author":"Fietta","year":"2002","journal-title":"J Chemother"},{"key":"10.1016\/j.phrs.2014.05.001_bib0245","first-page":"281","article-title":"Prevalence and chemosusceptibility of Neisseria meningitidis and Haemophilus influenzae in a population of central Italy","volume":"26","author":"Cresti","year":"2003","journal-title":"New Microbiol"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661814000607?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661814000607?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T05:26:42Z","timestamp":1538630802000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661814000607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":49,"alternative-id":["S1043661814000607"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2014.05.001","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is generic rifaximin still a poorly absorbed antibiotic? A comparison of branded and generic formulations in healthy volunteers","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2014.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}